-
Ariosa Diagnostics, Inc v. Sequenom, Inc DC CAFC
- 3:11-cv-06391
- N.D. Cal.
- Judge: Susan Y. Illston
+1
- Filed: 12/19/2011
- Closed: 11/20/2013
- Latest Docket Entry: 06/06/2018
- PACER
1
Plaintiff
1
Defendant
0
Accused
Products
1
Patent-in-Suit
703
Days in
Litigation
-
Ariosa Diagnostics, Inc v. Sequenom, Inc DC CAFC
- 3:11-cv-06391
- N.D. Cal.
- Judge: Susan Y. Illston
+1
- Filed: 12/19/2011
- Closed: 11/20/2013
- Latest Docket Entry: 06/06/2018
- PACER
Market Sector
Medical
Assigned Judge
Previously Presiding
Elizabeth D. Laporte (until 03/11/2012)
Outcome Summary
Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method for detecting a paternally inherited nucleic acid of fetal origin performed on a maternal serum or plasma sample from a pregnant female, which method comprises</claim-text> amplifying a paternally inherited nucleic acid from the serum or
view more
|
Invalid (101)
Entry 254 |
2 |
The method according to claim <HIL><BOLD>1</BOLD></HIL>, wherein the foetal nucleic acid is amplified by the polymerase chain reaction.
|
Invalid (101)
Entry 254 |
4 |
The method according to claim <HIL><BOLD>1</BOLD></HIL>, wherein the foetal nucleic acid is detected by means of a sequence specific probe.
|
Invalid (101)
Entry 254 |
5 |
The method according to claim <HIL><BOLD>1</BOLD></HIL>, wherein the presence of a foetal nucleic acid sequence from the Y chromosome is detected.
|
Invalid (101)
Entry 254 |
8 |
The method according to claim <HIL><BOLD>1</BOLD></HIL>, wherein the presence of a foetal nucleic acid from a paternally-inherited non-Y chromosome is detected.
|
Invalid (101)
Entry 254 |
19 |
The method according to claim <HIL><BOLD>1</BOLD></HIL>, wherein the sample contains foetal DNA at a fractional concentration of total DNA of at least about 0.14%, without subjecting it to a foetal DNA enrichment step.
|
Invalid (101)
Entry 254 |
20 |
The method according to claim <HIL><BOLD>19</BOLD></HIL>, wherein the fractional concentration of foetal DNA is at least about 0.39%.
|
Invalid (101)
Entry 254 |
21 |
A method of performing a prenatal diagnosis, which method comprises the steps of:</claim-text> (i) providing a maternal blood sample; (ii) separating the sample into a cellular and a non-cellular fraction; (iii) detecting the presence of a nucleic
view more
|
Invalid (101)
Entry 254 |
22 |
The method according to claim <HIL><BOLD>21</BOLD></HIL>, wherein the non-cellular fraction as used in step (iii) is a plasma fraction.
|
Invalid (101)
Entry 254 |
24 |
A method for detecting a paternally inherited nucleic acid on a maternal blood sample, which method comprises:</claim-text> removing all or substantially all nucleated and anucleated cell populations from the blood sample, amplifying a paternally
view more
|
Invalid (101)
Entry 254 |
25 |
A method for performing a prenatal diagnosis on a maternal blood sample, which method comprises</claim-text> obtaining a non-cellular fraction of the blood sample amplifying a paternally inherited nucleic acid from the non-cellular fraction and
view more
|
Invalid (101)
Entry 254 |
-
Infringement
Ariosa Diagnostics, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Arisa Test | US 6,258,540 B1 | All Asserted Claims |
No infringement
Entry 263
|